Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis
Biotechnology and Bioengineering · 2024-10 · 121 (10) · 3338-3350
DOI: 10.1002/bit.28800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 04.07.2024. Verfasst von Xian Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi, China. Hauptthemen laut MEDLINE: Bacillus subtilis, Metabolic Engineering, Vitamin K 2. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Menaquinone‐7 (MK‐7), a form of vitamin K2, supports bone health and prevents arterial calcification. Microbial fermentation for MK‐7 production has attracted widespread attention because of its low cost and short production cycles. However, insufficient substrate supply, unbalanced precursor synthesis, and low catalytic efficiency of key enzymes severely limited the efficiency of MK‐7 synthesis. In this study, utilizing Bacillus subtilis BSAT01 (with an initial MK‐7 titer of 231.0 mg/L) obtained in our previous study, the glycerol metabolism pathway was first enhanced to increase the 3‐deoxy‐arabino‐heptulonate 7‐phosphate (DHAP) supply, which led to an increase in MK‐7 titer to 259.7 mg/L. Subsequently, a combination of knockout strategies predicted by the genome‐scale metabolic model etiBsu1209 was employed to optimize the central carbon metabolism pathway, and the resulting strain showed an increase in MK‐7 production from 259.7 to 318.3 mg/L. Finally, model predictions revealed the methylerythritol phosphate pathway as the major restriction pathway, and the pathway flux was increased by heterologous introduction (Introduction of Dxs derived from Escherichia coli ) and fusion expression (End‐to‐end fusion of two enzymes by a linker peptide), resulting in a strain with a titer of 451.0 mg/L in a shake flask and 474.0 mg/L in a 50‐L bioreactor. This study achieved efficient MK‐7 synthesis in B. subtilis , laying the foundation for large‐scale MK‐7 bioproduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi, China.
- Science Center for Future Foods, Jiangnan University, Wuxi, China.
- Food Laboratory of Zhongyuan, Jiangnan University, Wuxi, China.
- Richen Bioengineering Co., Ltd., Nantong, China.
- Jiaxing Institute of Future Food, Jiaxing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, X., Bi, X., Li, G., Cui, S., Xu, X., Liu, Y., Li, J., Du, G., Lv, X., & Liu, L. (2024). Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis. Biotechnology and Bioengineering, 121(10), 3338-3350. https://doi.org/10.1002/bit.28800
Vancouver
Sun X, Bi X, Li G, Cui S, Xu X, Liu Y, et al. Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis. Biotechnology and Bioengineering. 2024;121(10):3338-3350. doi:10.1002/bit.28800
BibTeX
@article{Sun2024,
author = {Sun, Xian and Bi, Xinyu and Li, Guyue and Cui, Shixiu and Xu, Xianhao and Liu, Yanfeng and Li, Jianghua and Du, Guocheng and Lv, Xueqin and Liu, Long},
title = {Combinatorial metabolic engineering of Bacillus subtilis for menaquinone‐7 biosynthesis},
journal = {Biotechnology and Bioengineering},
year = {2024},
volume = {121},
number = {10},
pages = {3338--3350},
doi = {10.1002/bit.28800}
}
EUVIMED